The value of BNP and cTnT in the diagnosis and treatment of symptomatic patent ductus arteriosus in premature infants

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025556

Enrollment

Unknown

Registered

2019-09-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent ductus arteriosus in premature infants

Interventions

Gold Standard:Echocardiography

Index test:BNP and troponin T

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. From October 30, 2018 to April 30, 2020, 100 premature infants were hospitalized in our department; 2. Gestational age 28-34 weeks, suitable for gestational age; 3. Admission within 24 hours after birth.

Exclusion criteria

Exclusion criteria: 1. Concomitant congenital heart disease or severe suffocation; 2. Severe pulmonary hypertension, septicaemia, severe anemia and renal dysfunction occurred within 1 week after birth; 3. Grade III/IV intraventricular hemorrhage has been confirmed by cranial ultrasonography within 4 days after birth; 4. Incomplete information.

Design outcomes

Primary

Measure	Time frame
BNP;cTn;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactZhang Pingping

Tianjin First Central Hospital

ppzhang815@163.com+86 13702009383

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026